Polyclonal and monoclonal antibodies against human tissue inhibitor of metalloproteinases (TIMP) and the design of an enzyme-linked immunosorbent assay to measure TIMP

Clark, Ian M.; Powell, Liz; Wright, John; Cawston, Tim E.

doi:10.1016/s0934-8832(11)80211-8

Cited by 51 publications

(18 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum concentrations of TIMP-1 exceeded serum levels of both immunoreactive MMP-1 and MMP-3. However, in contrast to recently published ELISA procedures for TIMP-1 determination (32,33), our EIA detects not only free TIMP-1, but also TIMP-1 complexed to MMPs (27). Further, MMP-1 and MMP-3 may also be complexed to TIMP-2.…”

Section: Discussionmentioning

confidence: 72%

Serum levels of collagenase, stromelysin‐1, and timp‐1

Manicourt¹,

Fujimoto

Obata

et al. 1994

Arthritis & Rheumatism

View full text Add to dashboard Cite

Objective. To measure serum levels of collagenase (MMP-l), stromelysin-1 (MMP3), and tissue inhibitor of matrix metalloproteinaise+l (TIMP-1) in normal subjects and in patients with osteoarthritis (OA), and to assess how these correlate with biochemical and clinical indicators of disease activity in OA.Methods. Specific iimmunoassays were used to measure MMPs, TIMP-1, and antigenic keratan sulfate (KS). The total area of cartilage affected by the disease was measured (expressed as an articular index).Results. In the normal population (n = 118), the serum concentration of MlrlP-3, but not of MMP-1 or TIMP-1, increased with age and was approximately 2 times higher in males thinn in females. In the OA patients (n = 33), the serum levels of MMP-3, but not of MMP-1 or TIMP-1, were significantly elevated and correlated strongly with thle articular index but poorly with objective and subjective functional capacity scores as well as with serum levels of antigenic KS and systemic parameters of inflammation.

show abstract

Section: Discussionmentioning

confidence: 72%

Serum levels of collagenase, stromelysin‐1, and timp‐1

Manicourt¹,

Fujimoto

Obata

et al. 1994

Arthritis & Rheumatism

View full text Add to dashboard Cite

show abstract

“…TIMP-1 was measured using a double-antibody sandwich ELISA as previously described (41). The antibody was developed in Dr. Cawston's laboratory.…”

Section: Methodsmentioning

confidence: 99%

Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis

Cunnane¹,

FitzGerald²,

Beeton³

et al. 2001

Arthritis & Rheumatism

Self Cite

123

View full text Add to dashboard Cite

“…31 The intra-and interassay CsV to evaluate MMP-9 levels were 4.9%, and 8.6%. 32 The intra-and interassay CsV for measuring TIMP-1 levels were 9.3%, and 13.1%, respectively, 33 while those for measuring TIMP-2 levels were 5.4%, and 5.9%, respectively. 34 …”

Section: Assessmentsmentioning

confidence: 99%

Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia

Derosa

Maffioli

D’Angelo

et al. 2009

CIM

View full text Add to dashboard Cite

Clin Invest Med 2009; 32 (2): E124-E132. AbstractPurpose: To evaluate the distribution of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), and their specific inhibitors in a sample of patients affected by mild dyslipidemia but not yet treated with antihyperlipidemic drugs. Methods: One hundred and sixty-eight Caucasian patients aged 18 yr of either sex with combined dyslipidemia and who had never previously taken lipid-lowering medications were evaluated. As a control population, we enrolled 179 Caucasian healthy subjects, aged 18 yr of either sex. We evaluated body mass index (BMI), fasting plasma glucose (FPG), fasting plasma insulin (FPI), homeostasis model assessment (HOMA index), systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), triglycerides (Tg), lipoprotein(a) Lp(a), plasminogen activator inhibitor-1 (PAI-1), homocysteine (Hct), fibrinogen (Fg), high sensitivity Creactive protein (Hs-CRP), adiponectin (ADP), MMP-2, MMP-9, tissue inhibitors of metalloproteinase-1 (TIMP-1), and tissue inhibitors of metalloproteinase-2 (TIMP-2). Results: TC, Tg, and LDL-C were higher (P << 0.05, P << 0.01 and P << 0.05, respectively) in the dyslipidemic group, while HDL-C levels were lower (P << 0.01) compared with the control group. Increases of PAI-1, Hct, Fg, and Hs-CRP (P << 0.01, P << 0.05, P << 0.05, and P << 0.05, respectively) were present in the dyslipidemic group, while ADP level was lower (P << 0.01) in the dyslipidemic patients compared with controls. MMP-2, MMP-9, TIMP-1, and TIMP-2 levels were higher (P << 0.0001) in the dyslipidemic group. Conclusions: Combined hyperlipidemic patients have increased levels of prothrombotic and microinflammatory parameters and higher levels of MMP-2, MMP-9, TIMP-1, and TIMP-2 than control subjects. The prognostic importance of this observation has to be evaluated in adequately designed prospective studies. List of Abbreviations

show abstract

Polyclonal and monoclonal antibodies against human tissue inhibitor of metalloproteinases (TIMP) and the design of an enzyme-linked immunosorbent assay to measure TIMP

Cited by 51 publications

References 28 publications

Serum levels of collagenase, stromelysin‐1, and timp‐1

Serum levels of collagenase, stromelysin‐1, and timp‐1

Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis

Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia

Contact Info

Product

Resources

About